From bloodjournal.hematologylibrary.org by guest on June 7, 2013. For personal use only.
Prepublished online April 24, 2003; doi:10.1182/blood-2002-11-3422
Placenta growth factor activates monocytes and correlates with sickle cell disease severity Natalya Perelman, Suresh K Selvaraj, Sandeep Batra, Lori R Luck, Anat Erdreich-Epstein, Thomas D Coates, Vijay K Kalra and Punam Malik
Articles on similar topics can be found in the following Blood collections Hemostasis, Thrombosis, and Vascular Biology (2497 articles) Phagocytes (973 articles) Red Cells (1174 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml
Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.
From bloodjournal.hematologylibrary.org by guestApril on June 2013. For personal use only. Blood First Edition Paper, prepublished online 24,7,2003; DOI 10.1182/blood-2002-11-3422
Placenta Growth Factor Activates Monocytes and Correlates with Sickle Cell Disease Severity.
Natalya Perelman1, Suresh K. Selvaraj2, Sandeep Batra1, Lori R. Luck1, Anat Erdreich-Epstein1, Thomas D. Coates1, Vijay K. Kalra2 and Punam Malik1
Running Title: Placenta Growth Factor and Sickle Cell Disease Severity
Division of Hematology-Oncology, Childrens Hospital Los Angeles, Departments of Pediatrics and Pathology1, and the Department of Biochemistry & Molecular Biology2, Keck School of Medicine, University of Southern California.
Corresponding Author: Punam Malik, MD Division of Hematology-Oncology, Mail Stop 54 Childrens Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027 Phone: 323-669-5438 Fax: 323-913-3087 Email:
[email protected]
This work was supported by the USC Comprehensive Sickle Cell Center (CSSC) Grant HLPO1-48484 and the Sickle Cell Disease Association of America (SCDAA). Punam Malik is the recipient of the USC CSSC scholar award and Lori Luck the recipient of the SCDAA fellowship award.
Copyright (c) 2003 American Society of Hematology
From bloodjournal.hematologylibrary.org by guest on June 7, 2013. For personal use only.
ABSTRACT Sickle cell disease (SCD) results in chronic hypoxia and secondarily increased erythropoietin concentrations. Leukocytosis and activated monocytes are also observed in SCD in absence of infection or vaso-occlusion (steady state), the reasons for which are unknown. We found that erythroid cells produced placenta growth factor (PlGF), an angiogenic growth factor belonging to the vascular endothelial growth factor (VEGF) family, and its expression was induced in bone marrow CD34+ progenitor cells in the presence of erythropoietin. Furthermore, the steady state circulating PlGF levels in subjects with severe SCD [ 3 vaso-occlusive crises (VOC)/year] were 18.5 ± 1.2 pg/mL (n=9) compared to 15.5 ± 1.2 pg/mL (n=13) in those with mild SCD (
